TREATMENT BENEFITS OF UPADACITINIB BASED ON DISEASE SEVERITY, DISEASE DURATION AND NUMBER OF PRIOR BIOLOGICS IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: A POST-HOC ANALYSIS OF PHASE 3 TRIAL DATA

Edward V. Loftus  1     Joana Torres  2     Gareth Parkes  3, 4     Ken Takeuchi  5     Si Xuan  6     James Crooks     Justin Klaff     Yuri Sanchez Gonzalez     Silvio Danese  7    
1 Mayo Clinic College of Medicine and Science, Rochester, United States
2 Hospital Beatriz ├éngelo, Lisbon, Portugal
3 Barts and the London School of Medicine and Dentistry, London, United Kingdom
4 Barts Health NHS Trust, London, United Kingdom
5 IBD Center, Tsujinaka Hospital Kashiwanoha, Kashiwa, Japan
6 AbbVie, Inc., North Chicago, United States
7 Vita-Salute San Raffaele University - IRCCS San Raffaele Scientific Institute, Milan, Italy

Topic
IBD

Conference
UEG Week 2023

Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing